This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Leukocyte immunoglobulin-like receptor subfamily A member 5.
.
Human | |
---|---|
Gene Name: | LILRA5 |
Uniprot: | A6NI73 |
Entrez: | 353514 |
Belongs to: |
---|
No superfamily |
LILRA5; LILRC1
Mass (kDA):
32.755 kDA
Human | |
---|---|
Location: | 19q13.42 |
Sequence: | 19; NC_000019.10 (54307070..54313166, complement) |
Cell membrane; Single-pass type I membrane protein.; [Isoform 3]: Secreted.
If you are searching for a high-affinity LILRA5 marker antigen, you have found it. Boster offers a wide range of high-affinity prima antibodies. Their antibodies have been well validated on Western Blotting, Immunohistochemistry, and ELISA. Continue reading for more information. This article will focus on Boster Bio's best uses for the LILRA5Marker.
Traditionally, antibodies were categorized according to the number or heavy chains present. Heavy chains (alpha and beta chains) bind to antigens in variable regions. Light chains, by contrast, have constant areas. Heavy chains, also called "chains", are composed mainly of light chains segments, which are known as variable regions. Researchers can identify antibodies using the LILRA5 marker, which allows them to determine the number of light chain segments.
LILRA5 can be used to identify the antigen "Fab'. In addition to the LILRA5 marker, Boster Bio produces high-affinity antibodies based on this marker. These antibodies are more sensitive than other antigens and can also detect the presence of a wide range of cellular components. Boster Bio high affinity primary antibodies using LILRA5 mark are excellent candidates for detection in a variety disease.
The LILRB4 antigen is an integral component of human leukemia cells. It helps AML migrate. The antibodies taken from human serum attach to the receptor's antigen binding fragment. When treated with ten% human serum, they inhibit LILRB4 reporter-cell activation. As a positive control, the mouse serum was used. These antibodies detected activation of LILRB4 via APOE using the Boster Bio high affinity primary antibodies. They also used the LILRA5 marker.
BLI analysis was used to identify LILRB4 specific mAbs. These are representative mAbs which recognize different epitope bindings. The LILRB4 ECDFc fusion proteins include full-length mutated versions of D1 and D2 as well as their full length counterparts. These proteins are bound to the ECD by the mAb 128-3
Researchers working on SAA first identified the LILRA5 marker. It is expressed in mDCs and could play a role during SAA immune pathogenesis. Future plans for this marker include the determination of its function and the identification of a potential therapeutic use. The LILRA5 candidate gene remains intriguing for now. To understand how this gene affects immunity function in humans, however, more research is needed.
The LILRA5 proteins have two forms: a membranebound form and one that is soluble. Both of these forms exhibit cleavage downstream of Ala51. The human and mouse LILRA5 proteins share 58% identity. Further, LILRA5 has a high rate of homology with the LILRA5 gene, making it a valuable marker in AML research.
The LILRA5 protein was linked to the common Fc receptor gamma chain. Recent studies have revealed that LILRA5 induces the selective production of proinflammatory cytokines when it crosses-linked to MHC molecules. Future research for the LILRA5 mark should focus on determining LILRA5's function in different autoimmune disorders. The LILRA5 protein is a part of the LILR family of innate immune receptors.
PMID: 10941842 by Wende H., et al. Extensive gene duplications and a large inversion characterize the human leukocyte receptor cluster.
PMID: 12393390 by Borges L., et al. LIR9, an immunoglobulin-superfamily-activating receptor, is expressed as a transmembrane and as a secreted molecule.